Positive News Sentiment NASDAQ:PROK ProKidney - PROK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $12.62 +1.67 (+15.25%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.96▼$13.2150-Day Range$8.43▼$13.7852-Week Range$5.14▼$14.19Volume433,888 shsAverage VolumeN/AMarket Capitalization$323.58 millionP/E RatioN/ADividend YieldN/APrice Target$15.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media ProKidney MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside20.4% Upside$15.20 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.89) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector838th out of 1,005 stocksBiological Products, Except Diagnostic Industry147th out of 168 stocks 2.4 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.20, ProKidney has a forecasted upside of 20.4% from its current price of $12.62.Amount of Analyst CoverageProKidney has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PROK. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 3.8 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProKidney this week, compared to 0 articles on an average week.Search Interest1 people have searched for PROK on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have not sold or bought any company stock.Percentage Held by Insiders44.60% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to grow in the coming year, from ($1.89) to ($0.67) per share. Previous Next See Top Rated MarketRank™ Stocks Here About ProKidney (NASDAQ:PROK) StockProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Stock News HeadlinesMarch 3, 2023 | finance.yahoo.comProKidney to Participate in TD Cowen’s 43rd Annual Health Care ConferenceFebruary 21, 2023 | morningstar.comProKidney Corp Ordinary Shares - Class AMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.January 11, 2023 | finance.yahoo.comProKidney’s stock jumps 29%January 10, 2023 | msn.comProKidney surges 20% on cell therapy potential to slow dialysis for chronic kidney diseaseJanuary 10, 2023 | finance.yahoo.comProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney DiseaseDecember 27, 2022 | finance.yahoo.comA Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK)December 22, 2022 | finance.yahoo.comProKidney to Present at the J.P. Morgan 41st Annual Healthcare ConferenceMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.December 17, 2022 | money.usnews.comProKidney Corp - Ordinary Shares - Class ANovember 16, 2022 | finance.yahoo.comProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth PlansNovember 15, 2022 | bizjournals.comWinston-Salem clinical-stage company reports increase in cash, expenses during Q3 as result of going publicNovember 14, 2022 | finance.yahoo.comProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsNovember 12, 2022 | finance.yahoo.comProKidney to Participate in Upcoming Investor ConferencesNovember 3, 2022 | finance.yahoo.comProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney DiseaseOctober 15, 2022 | benzinga.comProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2022October 14, 2022 | finance.yahoo.comProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022October 14, 2022 | benzinga.comCitigroup Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $16September 8, 2022 | finance.yahoo.comProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 31, 2022 | finance.yahoo.comProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor RelationsAugust 11, 2022 | finance.yahoo.comProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 28, 2022 | finance.yahoo.comProKidney Corp. (PROK)July 27, 2022 | finance.yahoo.comProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical AffairsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Company Calendar Today3/26/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$15.20 High Stock Price Forecast$18.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+20.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio52.78 Quick Ratio52.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book-38.24Miscellaneous Outstanding Shares25,640,000Free Float14,205,000Market Cap$323.58 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Timothy A. Bertram D.V.M. (Age 67)Ph.D., Founder, CEO & Director Mr. James Coulston CPA (Age 46)Chief Financial Officer Dr. Deepak Jain Ph.D. (Age 68)Chief Operating Officer Dr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., Sr. VP of Investor RelationsMr. Todd C. Girolamo Esq. (Age 57)J.D., M.B.A., Chief Legal Officer & Corp. Sec. Dr. Libbie P. McKenzie M.D. (Age 49)Chief Medical Officer Ms. Ashley H. JohnsSr. VP of Clinical OperationsDr. Joseph M. Stavas M.D.Sr. VP of Clinical Devel.Dr. Darin J. Weber Ph.D. (Age 54)Sr. VP of Regulatory Devel. Dr. Kerry Cooper M.D.Sr. VP of Medical AffairsMore ExecutivesKey CompetitorsVectivBioNASDAQ:VECTAtara BiotherapeuticsNASDAQ:ATRASOPHiA GENETICSNASDAQ:SOPHCaribou BiosciencesNASDAQ:CRBUOutlook TherapeuticsNASDAQ:OTLKView All CompetitorsInstitutional OwnershipMorgan StanleyBought 595,839 shares on 2/15/2023Ownership: 42.697%State of Wisconsin Investment BoardBought 30,841 shares on 2/15/2023Ownership: 0.120%Legal & General Group PlcBought 8,286 shares on 2/15/2023Ownership: 0.032%AmundiBought 23,822 shares on 2/14/2023Ownership: 0.093%Geode Capital Management LLCBought 30,253 shares on 2/13/2023Ownership: 0.518%View All Institutional Transactions PROK Stock - Frequently Asked Questions Should I buy or sell ProKidney stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PROK shares. View PROK analyst ratings or view top-rated stocks. What is ProKidney's stock price forecast for 2023? 6 Wall Street research analysts have issued 12-month price objectives for ProKidney's shares. Their PROK share price forecasts range from $13.00 to $18.00. On average, they anticipate the company's stock price to reach $15.20 in the next year. This suggests a possible upside of 20.4% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts. How have PROK shares performed in 2023? ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have increased by 84.0% and is now trading at $12.62. View the best growth stocks for 2023 here. When is ProKidney's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our PROK earnings forecast. What is ProKidney's stock symbol? ProKidney trades on the NASDAQ under the ticker symbol "PROK." Who are ProKidney's major shareholders? ProKidney's stock is owned by a number of retail and institutional investors. Top institutional investors include Social Capital Group LLC (51.77%), Morgan Stanley (42.70%), Brown University (3.90%), Bank of America Corp DE (0.77%), Geode Capital Management LLC (0.52%) and Swiss National Bank (0.29%). How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProKidney's stock price today? One share of PROK stock can currently be purchased for approximately $12.62. How much money does ProKidney make? ProKidney (NASDAQ:PROK) has a market capitalization of $323.58 million. How can I contact ProKidney? ProKidney's mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The official website for the company is www.prokidney.com. The company can be reached via phone at 336-999-7028 or via email at lroth@burnsmc.com. This page (NASDAQ:PROK) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.